Today (2017 C.E. - 2025 C.E.)

This archive spans the years 2017 through 2025, a period marked by rapid advances in clean energy, medicine, technology, and social equity. It collects documented breakthroughs, policy wins, and scientific achievements from the present era. If you want evidence that progress is real and ongoing, this is where to look.

Rhinos, for article on white rhino rewilding

Africa NGO purchases world’s largest captive rhino population to rewild 2,000 across the continent

More than 2,000 white rhinos — roughly 15% of the wild southern white rhino population — are heading back to the wild, thanks to a landmark purchase by African Parks. The conservation NGO bought the entire Platinum Rhino herd and plans to release the animals across protected sites in southern Africa over the next decade. The rhinos lived in semi-wild conditions on the ranch, and experts believe they’ll adapt quickly to true wilderness, drawing on African Parks’ experience relocating thousands of animals across the continent. If it succeeds, this rewilding effort could become a defining chapter in one of conservation’s greatest comeback stories — and a hopeful blueprint for protecting threatened species worldwide.

Pig embryo with human kidney, for article on pig-human chimera

Chinese researchers grow world’s first human organ inside a non-human animal

Human kidney tissue has been grown inside a pig embryo for the first time, with roughly half the cells in the developing kidney being human. Researchers in Guangzhou reprogrammed adult human cells, then injected them into pig embryos engineered to leave a “gap” where their own kidneys would form. The human cells moved in and self-organized into an early-stage kidney structure over 28 days of gestation. It’s not a transplantable organ, and real ethical questions remain about keeping human cells out of pig brains. But for the 100,000 Americans waiting for a kidney right now, this is a meaningful step toward a future where no one dies waiting.

Pills and syringe, for article on fentanyl vaccine human trials

Scientists preparing first human trials for vaccines that block the effects of deadly opioids

Fentanyl vaccines are heading into their first human trials, with Phase 1 testing set to begin in early 2024 at Columbia University. Developed by researchers at the University of Montana and University of Washington, the vaccines train the immune system to grab fentanyl molecules in the bloodstream, like a sponge, before they can reach the brain. That means no high, and no slowed breathing, which is what makes overdoses fatal. The team is especially focused on people in the first two years of recovery, when relapse risk is highest. If it works, this could become a powerful new tool in a crisis that has demanded every bit of compassion and ingenuity we can offer.